-
A.
Meindl,
K.
Eirich,
S.
Engert,
A.
Becker,
D.
Endt,
N.
Ditsch,
R.
Schmutzler,
D.
Schindler
(2012)
Germline RAD51C mutations confer susceptibility to ovarian cancer
Nature Genetics, 44
-
M.
Kriege,
C.
Brekelmans,
C.
Boetes,
Peter
Besnard,
H.
Zonderland,
I.
Obdeijn,
R.
Manoliu,
T.
Kok,
H.
Peterse,
M.
Tilanus-Linthorst,
S.
Muller,
S.
Meijer,
J.
Oosterwijk,
L.
Beex,
R.
Tollenaar,
H.
Koning,
E.
Rutgers,
J.
Klijn
(2004)
Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition.
The New England journal of medicine, 351 5
-
E.
Pujade-Lauraine,
J.
Ledermann,
R.
Penson,
A.
Oza,
J.
Korach,
T.
Huzarski,
A.
Poveda,
S.
Pignata,
M.
Friedlander,
N.
Colombo
(2017)
Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: Results from the phase III SOLO2 study
Gynecologic Oncology, 145
-
P.
Fong,
D.
Boss,
T.
Yap,
A.
Tutt,
P.
Wu,
M.
Mergui-Roelvink,
Peter
Mortimer,
H.
Swaisland,
A.
Lau,
M.
O’Connor,
A.
Ashworth,
J.
Carmichael,
S.
Kaye,
J.
Schellens,
J.
Bono
(2009)
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
The New England journal of medicine, 361 2
-
J.
Piek,
R.
Verheijen,
P.
Kenemans,
L.
Massuger,
H.
Bulten,
P.
Diest
(2003)
BRCA1/2-related ovarian cancers are of tubal origin: a hypothesis.
Gynecologic oncology, 90 2
-
D.
Tan,
C.
Rothermundt,
K.
Thomas,
E.
Bancroft,
R.
Eeles,
S.
Shanley,
A.
Ardern-jones,
A.
Norman,
S.
Kaye,
M.
Gore
(2008)
"BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 34
-
U.
Matulonis,
P.
Harter,
C.
Gourley,
M.
Friedlander,
I.
Vergote,
G.
Rustin,
A.
Fielding,
S.
Spencer,
D.
Parry,
J.
Ledermann
(2015)
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for post-progression PARP inhibitor therapy
Gynecologic Oncology, 137
-
J.
Struewing,
P.
Hartge,
S.
Wacholder,
Sonya
Baker,
M.
Berlin,
M.
McAdams,
Michelle
Timmerman,
L.
Brody,
M.
Tucker
(1997)
The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.
The New England journal of medicine, 336 20
-
Fangyi
Gu,
R.
Pfeiffer,
Samsiddhi
Bhattacharjee,
Summer
Han,
P.
Taylor,
Sonja
Berndt,
Han-Kwang
Yang,
A.
Sigurdson,
J.
Toro,
L.
Mirabello,
Mark
Greene,
N.
Freedman,
C.
Abnet,
S.
Dawsey,
N.
Hu,
Y.
Qiao,
T.
Ding,
A.
Brenner,
M.
García-Closas,
R.
Hayes,
L.
Brinton,
J.
Lissowska,
N.
Wentzensen,
C.
Kratz,
L.
Moore,
R.
Ziegler,
W.
Chow,
S.
Savage,
Laurie
Burdette,
M.
Yeager,
S.
Chanock,
N.
Chatterjee,
M.
Tucker,
A.
Goldstein,
Xiaohong
Yang
(2013)
Common genetic variants in the 9p21 region and their associations with multiple tumours
British Journal of Cancer, 108
-
(2013)
Association for Molecular Pathology et al. v. Myriad Genetics, Inc.: Supreme Court of the United States
-
K.
Savage,
K.
Matchett,
Eliana
Barros,
K.
Cooper,
G.
Irwin,
Julia
Gorski,
Katy
Orr,
Jekaterina
Vohhodina,
J.
Kavanagh,
A.
Madden,
Alexander
Powell,
L.
Manti,
S.
McDade,
B.
Park,
K.
Prise,
S.
McIntosh,
M.
Salto‐Tellez,
D.
Richard,
Christopher
Elliott,
D.
Harkin
(2014)
BRCA1 deficiency exacerbates estrogen-induced DNA damage and genomic instability.
Cancer research, 74 10
-
M.
Robson,
A.
Bradbury,
B.
Arun,
S.
Domchek,
J.
Ford,
H.
Hampel,
Stephen
Lipkin,
S.
Syngal,
D.
Wollins,
N.
Lindor
(2010)
American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 31
-
De-Kun
Li,
Marian
Willinger,
Diana
Petitti,
R.
Odouli,
Liyan
Liu,
Howard
Hoffman
(2005)
Use of a dummy (pacifier) during sleep and risk of sudden infant death syndrome (SIDS): population based case-control study
BMJ : British Medical Journal, 332
-
K.
Gelmon,
M.
Tischkowitz,
H.
Mackay,
K.
Swenerton,
A.
Robidoux,
K.
Tonkin,
H.
Hirte,
D.
Huntsman,
M.
Clemons,
B.
Gilks,
R.
Yerushalmi,
E.
Macpherson,
J.
Carmichael,
A.
Oza
(2011)
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
The Lancet. Oncology, 12 9
-
K.
Alsop,
S.
Fereday,
C.
Meldrum,
A.
deFazio,
C.
Emmanuel,
J.
George,
A.
Dobrovic,
M.
Birrer,
P.
Webb,
C.
Stewart,
M.
Friedlander,
S.
Fox,
D.
Bowtell,
G.
Mitchell
(2012)
BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 21
-
T.
Rebbeck,
H.
Lynch,
S.
Neuhausen,
S.
Narod,
L.
Veer,
J.
Garber,
G.
Evans,
C.
Isaacs,
M.
Daly,
E.
Matloff,
O.
Olopade,
B.
Weber
(2002)
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
The New England journal of medicine, 346 21
-
A.
Antoniou,
P.
Pharoah,
S.
Narod,
H.
Risch,
J.
Eyfjord,
J.
Hopper,
N.
Loman,
Hampus
Olsson,
O.
Johannsson,
Å.
Borg,
B.
Pasini,
P.
Radice,
S.
Manoukian,
D.
Eccles,
N.
Tang,
E.
Oláh,
H.
Anton-Culver,
E.
Warner,
J.
Lubiński,
J.
Gronwald,
B.
Górski,
H.
Tulinius,
S.
Thorlacius,
H.
Eerola,
H.
Nevanlinna,
K.
Syrjäkoski,
O.
Kallioniemi,
Deborah
Thompson,
Chris
Evans,
J.
Peto,
F.
Lalloo,
D.
Evans,
D.
Easton
(2003)
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
American journal of human genetics, 72 5
-
M.
Mirza,
B.
Monk,
J.
Herrstedt,
A.
Oza,
S.
Mahner,
A.
Redondo,
M.
Fabbro,
J.
Ledermann,
D.
Lorusso,
I.
Vergote,
N.
Ben-Baruch,
C.
Marth,
R.
Mądry,
R.
Christensen,
J.
Berek,
A.
Dørum,
A.
Tinker,
A.
Bois,
A.
González-Martín,
P.
Follana,
B.
Benigno,
P.
Rosenberg,
L.
Gilbert,
B.
Rimel,
J.
Buscema,
J.
Balser,
S.
Agarwal,
U.
Matulonis
(2016)
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
The New England journal of medicine, 375 22
-
E.
Castro,
C.
Goh,
D.
Olmos,
E.
Saunders,
D.
Leongamornlert,
M.
Tymrakiewicz,
N.
Mahmud,
Tokhir
Dadaev,
K.
Govindasami,
M.
Guy,
E.
Sawyer,
R.
Wilkinson,
A.
Ardern-jones,
Steve
Ellis,
D.
Frost,
S.
Peock,
D.
Evans,
M.
Tischkowitz,
T.
Cole,
R.
Davidson,
D.
Eccles,
C.
Brewer,
F.
Douglas,
M.
Porteous,
A.
Donaldson,
H.
Dorkins,
L.
Izatt,
J.
Cook,
S.
Hodgson,
M.
Kennedy,
L.
Side,
J.
Eason,
A.
Murray,
A.
Antoniou,
D.
Easton,
Z.
Kote-Jarai,
R.
Eeles
(2013)
Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 14
-
Y.
Drew,
J.
Ledermann,
G.
Hall,
D.
Rea,
R.
Glasspool,
M.
Highley,
G.
Jayson,
J.
Sludden,
J.
Murray,
D.
Jamieson,
S.
Halford,
G.
Acton,
Zoe
Backholer,
R.
Mangano,
A.
Boddy,
N.
Curtin,
R.
Plummer
(2016)
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer
British Journal of Cancer, 114
-
T.
Walsh,
S.
Casadei,
Ming
Lee,
C.
Pennil,
A.
Nord,
A.
Thornton,
Wendy
Roeb,
K.
Agnew,
S.
Stray,
A.
Wickramanayake,
B.
Norquist,
K.
Pennington,
Rochelle
Garcia,
M.
King,
E.
Swisher
(2011)
Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing
Proceedings of the National Academy of Sciences, 108
-
Jeff
Hall,
Ming
Lee,
B.
Newman,
Jan
Morrow,
L.
Anderson,
B.
Huey,
M.
King
(1990)
Linkage of early-onset familial breast cancer to chromosome 17q21.
Science, 250 4988
-
N.
Dubrawsky
(1989)
Cancer statistics
CA: A Cancer Journal for Clinicians, 39
-
Haijuan
Yang,
P.
Jeffrey,
Julie
Miller,
E.
Kinnucan,
Yutong
Sun,
N.
Thoma,
N.
Zheng,
Phang-lang
Chen,
Wen-Hwa
Lee,
N.
Pavletich
(2002)
BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.
Science, 297 5588
-
T.
Rebbeck,
N.
Kauff,
S.
Domchek
(2009)
Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers
JNCI Journal of the National Cancer Institute, 101
-
Ian
Jacobs,
U.
Menon,
Andy
Ryan,
A.
Gentry-Maharaj,
M.
Burnell,
Jatinderpal
Kalsi,
N.
Amso,
S.
Apostolidou,
E.
Benjamin,
D.
Cruickshank,
Danielle
Crump,
S.
Davies,
A.
Dawnay,
Stephen
Dobbs,
Gwendolen
Fletcher,
J.
Ford,
Keith
Godfrey,
Richard
Gunu,
M.
Habib,
Rachel
Hallett,
J.
Herod,
H.
Jenkins,
C.
Karpinskyj,
Simon
Leeson,
S.
Lewis,
William
Liston,
Alberto
Lopes,
T.
Mould,
John
Murdoch,
David
Oram,
D.
Rabideau,
K.
Reynolds,
Ian
Scott,
M.
Seif,
Aarti
Sharma,
Naveena
Singh,
Julie
Taylor,
Fiona
Warburton,
Martin
Widschwendter,
K.
Williamson,
R.
Woolas,
Lesley
Fallowfield,
Alistair
McGuire,
S.
Campbell,
Mahesh
Parmar,
S.
Skates
(2016)
Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial
Lancet (London, England), 387
-
P.
Fong,
T.
Yap,
D.
Boss,
C.
Carden,
M.
Mergui-Roelvink,
C.
Gourley,
J.
Grève,
J.
Lubiński,
S.
Shanley,
C.
Messiou,
R.
A’Hern,
A.
Tutt,
A.
Ashworth,
J.
Stone,
J.
Carmichael,
J.
Schellens,
J.
Bono,
S.
Kaye
(2010)
Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 15
-
Eunjung
Lee,
Huiyan
Ma,
R.
Mckean-Cowdin,
D.
Berg,
L.
Bernstein,
B.
Henderson,
G.
Ursin
(2008)
Effect of Reproductive Factors and Oral Contraceptives on Breast Cancer Risk in BRCA1/2 Mutation Carriers and Noncarriers: Results from a Population-Based Study
Cancer Epidemiology Biomarkers & Prevention, 17
-
Joyce
Liu,
William
Barry,
M.
Birrer,
Jung-Min
Lee,
R.
Buckanovich,
G.
Fleming,
Bj
Rimel,
M.
Buss,
S.
Nattam,
J.
Hurteau,
W.
Luo,
P.
Quy,
C.
Whalen,
Lisa
Obermayer,
Hang
Lee,
Eric
Winer,
E.
Kohn,
S.
Ivy,
U.
Matulonis
(2014)
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.
The Lancet. Oncology, 15 11
-
P.
Moorman,
L.
Havrilesky,
J.
Gierisch,
R.
Coeytaux,
W.
Lowery,
Rachel
Urrutia,
M.
Dinan,
Amanda
McBroom,
V.
Hasselblad,
G.
Sanders,
E.
Myers
(2013)
Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 33
-
J.
Lancaster,
C.
Powell,
N.
Kauff,
I.
Cass,
Lee-may
Chen,
K.
Lu,
D.
Mutch,
A.
Berchuck,
B.
Karlan,
T.
Herzog
(2015)
Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions.
Gynecologic oncology, 136 1
-
A.
Tone,
H.
Begley,
Monika
Sharma,
Joan
Murphy,
B.
Rosen,
T.
Brown,
P.
Shaw
(2008)
Gene Expression Profiles of Luteal Phase Fallopian Tube Epithelium from BRCA Mutation Carriers Resemble High-Grade Serous Carcinoma
Clinical Cancer Research, 14
-
H.
Bryant,
N.
Schultz,
H.
Thomas,
Kayan
Parker,
Dan
Flower,
Elena
Lopez,
S.
Kyle,
M.
Meuth,
N.
Curtin,
T.
Helleday
(2005)
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Nature, 434
-
M.
Post
(2011)
Are All Pelvic (Nonuterine) Serous Carcinomas of Tubal Origin
Yearbook of Pathology and Laboratory Medicine, 2011
-
N.
Tung,
S.
Domchek,
Z.
Stadler,
K.
Nathanson,
F.
Couch,
J.
Garber,
K.
Offit,
M.
Robson
(2016)
Counselling framework for moderate-penetrance cancer-susceptibility mutations
Nature Reviews Clinical Oncology, 13
-
R.
Bristow,
Rafael
Tomacruz,
D.
Armstrong,
E.
Trimble,
F.
Montz
(2002)
Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 5
-
S.
Narod,
H.
Risch,
R.
Moslehi,
A.
Dørum,
S.
Neuhausen,
H.
Olsson,
D.
Provencher,
P.
Radice,
G.
Evans,
S.
Bishop,
J.
Brunet,
B.
Ponder
(1998)
Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group.
The New England journal of medicine, 339 7
-
Stacy
Loeb,
A.
Gupta,
L.
Losonczy,
J.
Tosoian,
P.
Walsh
(2013)
Adult UrologyUrological Survey: Urological Oncology: Prostate CancerRe: Germline BRCA Mutations are Associated with Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate Cancer
The Journal of Urology, 190
-
J.
Berliner,
A.
Fay,
S.
Cummings,
Brittany
Burnett,
T.
Tillmanns
(2013)
NSGC Practice Guideline: Risk Assessment and Genetic Counseling for Hereditary Breast and Ovarian Cancer
Journal of Genetic Counseling, 22
-
S.
Sandhu,
W.
Schelman,
G.
Wilding,
V.
Moreno,
R.
Baird,
S.
Miranda,
Lucy
Hylands,
R.
Riisnaes,
M.
Forster,
A.
Omlin,
N.
Kreischer,
K.
Thway,
H.
Gevensleben,
Linda
Sun,
John
Loughney,
Manash
Chatterjee,
C.
Toniatti,
C.
Carpenter,
R.
Iannone,
S.
Kaye,
J.
Bono,
R.
Wenham
(2013)
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.
The Lancet. Oncology, 14 9
-
G.
Korpanty,
K.
Timms,
V.
Abkevich,
M.
Carey,
A.
Gutin,
Y.
Li,
J.
Li,
M.
Markman,
R.
Broaddus,
J.
Lanchbury,
K.
Lu,
G.
Mills,
B.
Hennessy
(2011)
Loss of heterozygosity (LOH) as a measure of whole-genome instability in ovarian cancer correlates with clinical outcomes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 15_suppl
-
O.
Ginsburg,
C.
Kim-sing,
W.
Foulkes,
P.
Ghadirian,
H.
Lynch,
P.
Sun,
S.
Narod,
Hereditary
Group
(2010)
BRCA1 and BRCA2 families and the risk of skin cancer
Familial Cancer, 9
-
Kelly
Bolton,
G.
Chenevix-Trench,
Cindy
Goh,
S.
Sadetzki,
S.
Ramus,
B.
Karlan,
D.
Lambrechts,
E.
Despierre,
D.
Barrowdale,
L.
McGuffog,
S.
Healey,
D.
Easton,
O.
Sinilnikova,
Javier
Benítez,
M.
García,
S.
Neuhausen,
Mitchell
Gail,
P.
Hartge,
S.
Peock,
D.
Frost,
D.
Evans,
R.
Eeles,
Andrew
Godwin,
M.
Daly,
A.
Kwong,
Edmond
Ma,
C.
Lázaro,
Ignacio
Blanco,
M.
Montagna,
E.
D'andrea,
M.
Nicoletto,
S.
Johnatty,
S.
Kjær,
Allan
Jensen,
E.
Høgdall,
E.
Goode,
B.
Fridley,
J.
Loud,
Mark
Greene,
P.
Mai,
Angela
Chetrit,
F.
Lubin,
G.
Hirsh-Yechezkel,
G.
Glendon,
I.
Andrulis,
A.
Toland,
L.
Senter,
Martin
Gore,
C.
Gourley,
C.
Michie,
Honglin
Song,
J.
Tyrer,
A.
Whittemore,
Valerie
McGuire,
W.
Sieh,
Ulf
Kristoffersson,
Håkan
Olsson,
Åke
Borg,
D.
Levine,
L.
Steele,
Mary
Beattie,
Salina
Chan,
Robert
Nussbaum,
K.
Moysich,
J.
Gross,
I.
Cass,
Christine
Walsh,
A.
Li,
R.
Leuchter,
O.
Gordon,
M.
García-Closas,
S.
Gayther,
S.
Chanock,
A.
Antoniou,
Paul
Pharoah
(2012)
Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.
JAMA, 307 4
-
S.
Buys,
E.
Partridge,
A.
Black,
C.
Johnson,
L.
Lamerato,
C.
Isaacs,
D.
Reding,
R.
Greenlee,
L.
Yokochi,
B.
Kessel,
E.
Crawford,
T.
Church,
G.
Andriole,
J.
Weissfeld,
M.
Fouad,
D.
Chia,
B.
O'Brien,
L.
Ragard,
J.
Clapp,
J.
Rathmell,
T.
Riley,
P.
Hartge,
P.
Pinsky,
Claire
Zhu,
G.
Izmirlian,
B.
Kramer,
A.
Miller,
Jian‐Lun
Xu,
P.
Prorok,
J.
Gohagan,
C.
Berg
(2011)
Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial.
JAMA, 305 22
-
J.
Iqbal,
A.
Ragone,
J.
Lubiński,
H.
Lynch,
P.
Møller,
P.
Ghadirian,
W.
Foulkes,
S.
Armel,
A.
Eisen,
S.
Neuhausen,
L.
Senter,
C.
Singer,
Peter
Ainsworth,
C.
Kim-sing,
N.
Tung,
E.
Friedman,
M.
Llacuachaqui,
S.
Ping,
S.
Narod
(2012)
The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers
British Journal of Cancer, 107
-
S.
Narod,
M.
Dubé,
J.
Klijn,
J.
Lubiński,
H.
Lynch,
P.
Ghadirian,
D.
Provencher,
K.
Heimdal,
P.
Møller,
M.
Robson,
K.
Offit,
C.
Isaacs,
B.
Weber,
E.
Friedman,
R.
Gershoni-baruch,
G.
Rennert,
B.
Pasini,
T.
Wagner,
M.
Daly,
J.
Garber,
S.
Neuhausen,
P.
Ainsworth,
H.
Olsson,
G.
Evans,
M.
Osborne,
F.
Couch,
W.
Foulkes,
E.
Warner,
C.
Kim-sing,
O.
Olopade,
N.
Tung,
H.
Saal,
J.
Weitzel,
S.
Merajver,
M.
Gauthier‐Villars,
H.
Jernstrom,
P.
Sun,
J.
Brunet
(2002)
Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
Journal of the National Cancer Institute, 94 23
-
B.
Norquist,
M.
Harrell,
M.
Brady,
T.
Walsh,
Ming
Lee,
S.
Gulsuner,
S.
Bernards,
S.
Casadei,
Qian
Yi,
R.
Burger,
J.
Chan,
S.
Davidson,
R.
Mannel,
P.
DiSilvestro,
H.
Lankes,
N.
Ramirez,
M.
King,
E.
Swisher,
M.
Birrer
(2016)
Inherited Mutations in Women With Ovarian Carcinoma.
JAMA oncology, 2 4
-
J.
Thigpen
(2012)
Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer
Yearbook of Oncology, 2012
-
S.
Narod,
H.
Risch,
R.
Moslehi,
A.
Dørum,
S.
Neuhausen,
H.
Olsson,
D.
Provencher,
P.
Radice,
G.
Evans,
S.
Bishop,
J.
Brunet,
B.
Ponder,
J.
Klijn
(1998)
Oral Contraceptives and the Risk of Hereditary Ovarian Cancer
Obstetrical & Gynecological Survey, 54
-
R.
Siegel,
K.
Miller,
A.
Jemal
(2016)
Cancer statistics, 2016
CA: A Cancer Journal for Clinicians, 66
-
A phase I–II study of the oral poly(ADP-ribose) polymerase inhibitor rucaparib in patients with germline BRCA1/2-mutated ovarian carcinoma or other solid tumors
-
K.
Gudmundsdottir,
A.
Ashworth
(2006)
The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability
Oncogene, 25
-
Evans
Dgr
(2010)
Risk of breast cancer in male BRCA2 carriers
Journal of Medical Genetics, 47
-
A.
Wright,
A.
Cronin,
Dana
Milne,
M.
Bookman,
R.
Burger,
D.
Cohn,
M.
Cristea,
J.
Griggs,
N.
Keating,
C.
Levenback,
G.
Mantia-Smaldone,
U.
Matulonis,
L.
Meyer,
J.
Niland,
J.
Weeks,
D.
O’Malley
(2015)
Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer.
Obstetrical & Gynecological Survey
-
Honglin
Song,
E.
Dicks,
S.
Ramus,
J.
Tyrer,
M.
Intermaggio,
J.
Hayward,
C.
Edlund,
David
Conti,
P.
Harrington,
Lindsay
Fraser,
S.
Philpott,
C.
Anderson,
Adam
Rosenthal,
A.
Gentry-Maharaj,
D.
Bowtell,
K.
Alsop,
M.
Cicek,
J.
Cunningham,
B.
Fridley,
J.
Alsop,
M.
Jimenez-Linan,
E.
Høgdall,
Claus
Høgdall,
Allan
Jensen,
S.
Kjaer,
J.
Lubiński,
T.
Huzarski,
A.
Jakubowska,
J.
Gronwald,
S.
Poblete,
Shashi
Lele,
Lara
Sucheston-Campbell,
K.
Moysich,
K.
Odunsi,
E.
Goode,
Usha
Menon,
Ian
Jacobs,
S.
Gayther,
Paul
Pharoah
(2015)
Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 26
-
L.
Cipak,
Norifumi
Watanabe,
T.
Bessho
(2006)
The role of BRCA2 in replication-coupled DNA interstrand cross-link repair in vitro
Nature Structural &Molecular Biology, 13
-
©.
Roy,
W.
McCluggage
(2011)
Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
Pathology, 43 5
-
P.
Chambon,
J.
Weill,
P.
Mandel
(1963)
Nicotinamide mononucleotide activation of new DNA-dependent polyadenylic acid synthesizing nuclear enzyme.
Biochemical and biophysical research communications, 11
-
C.
Loveday,
C.
Turnbull,
Emma
Ramsay,
D.
Hughes,
Elise
Ruark,
J.
Frankum,
Georgina
Bowden,
B.
Kalmyrzaev,
M.
Warren-Perry,
K.
Snape,
J.
Adlard,
J.
Barwell,
J.
Berg,
A.
Brady,
C.
Brewer,
G.
Brice,
C.
Chapman,
J.
Cook,
R.
Davidson,
A.
Donaldson,
F.
Douglas,
L.
Greenhalgh,
A.
Henderson,
L.
Izatt,
Ajith
Kumar,
F.
Lalloo,
Z.
Miedzybrodzka,
Patrick
Morrison,
J.
Paterson,
M.
Porteous,
M.
Rogers,
S.
Shanley,
L.
Walker,
D.
Eccles,
D.
Evans,
A.
Renwick,
S.
Seal,
C.
Lord,
A.
Ashworth,
J.
Reis-Filho,
A.
Antoniou,
N.
Rahman
(2011)
Germline mutations in RAD51D confer susceptibility to ovarian cancer
Nature Genetics, 43
-
P.
Broca
Traité des tumeurs
-
Y.
Miki,
J.
Swensen,
D.
Shattuck-Eidens,
P.
Futreal,
K.
Harshman,
S.
Tavtigian,
Qingyun
Liu,
C.
Cochran,
L.
Bennett,
W.
Ding,
R.
Bell,
J.
Rosenthal,
C.
Hussey,
Thanh
Tran,
M.
Mcclure,
C.
Frye,
T.
Hattier,
R.
Phelps,
A.
Haugen-Strano,
H.
Katcher,
Kazuko
Yakumo,
Z.
Gholami,
Daniel
Shaffer,
S.
Stone,
Steven
Bayer,
Christian
Wray,
R.
Bogden,
P.
Dayananth,
J.
Ward,
P.
Tonin,
S.
Narod,
Pamela
Bristow,
F.
Norris,
L.
Helvering,
P.
Morrison,
P.
Rosteck,
Mei
Lai,
J.
Barrett,
C.
Lewis,
S.
Neuhausen,
L.
Cannon-Albright,
D.
Goldgar,
R.
Wiseman,
A.
Kamb,
M.
Skolnick
(1994)
A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.
Science, 266 5182
-
D.
Kindelberger,
Yonghee
Lee,
A.
Miron,
M.
Hirsch,
C.
Feltmate,
F.
Medeiros,
M.
Callahan,
Elizabeth
Garner,
R.
Gordon,
C.
Birch,
R.
Berkowitz,
M.
Muto,
C.
Crum
(2007)
Intraepithelial Carcinoma of the Fimbria and Pelvic Serous Carcinoma: Evidence for a Causal Relationship
The American Journal of Surgical Pathology, 31
-
M.
Purnell,
W.
Whish
(1980)
Novel inhibitors of poly(ADP-ribose) synthetase.
The Biochemical journal, 185 3
-
W.
Hoskins,
W.
Mcguire,
M.
Brady,
H.
Homesley,
W.
Creasman,
M.
Berman,
H.
Ball,
J.
Berek
(1994)
The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma.
American journal of obstetrics and gynecology, 170 4
-
E.
Swisher,
K.
Lin,
A.
Oza,
C.
Scott,
H.
Giordano,
James
Sun,
G.
Konecny,
R.
Coleman,
A.
Tinker,
D.
O’Malley,
R.
Kristeleit,
Ling
Ma,
K.
Bell-McGuinn,
J.
Brenton,
J.
Cragun,
A.
Oaknin,
I.
Ray-Coquard,
M.
Harrell,
E.
Mann,
S.
Kaufmann,
A.
Floquet,
A.
Leary,
T.
Harding,
S.
Goble,
L.
Maloney,
J.
Isaacson,
A.
Allen,
L.
Rolfe,
R.
Yelensky,
M.
Raponi,
I.
McNeish
(2017)
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
The Lancet. Oncology, 18 1
-
D.
Saslow,
C.
Boetes,
W.
Burke,
S.
Harms,
M.
Leach,
C.
Lehman,
E.
Morris,
E.
Pisano,
M.
Schnall,
S.
Sener,
Robert
Smith,
E.
Warner,
M.
Yaffe,
Kimberly
Andrews,
C.
Russell
(2007)
American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography
CA: A Cancer Journal for Clinicians, 57
-
J.
Lacey,
M.
Greene,
S.
Buys,
D.
Reding,
T.
Riley,
C.
Berg,
R.
Fagerstrom,
P.
Hartge
(2006)
Ovarian Cancer Screening in Women With a Family History of Breast or Ovarian Cancer
Obstetrics & Gynecology, 108
-
FDA grants accelerated approval to new treatment for advanced ovarian cancer
-
H.
Falconer,
L.
Yin,
H.
Grönberg,
D.
Altman
(2015)
Ovarian cancer risk after salpingectomy: a nationwide population-based study.
Journal of the National Cancer Institute, 107 2
-
E.
Woodward,
HV
Sleightholme,
AM
Considine,
S.
Williamson,
J.
McHugo,
DG
Cruger
(2007)
Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high‐risk and population risk women is ineffective
BJOG: An International Journal of Obstetrics & Gynaecology, 114
-
S.
Rubin,
I.
Benjamin,
K.
Behbakht,
Hiroyuki
Takahashi,
M.
Morgan,
V.
Livolsi,
A.
Berchuck,
M.
Muto,
J.
Garber,
Barbara
Weber,
H.
Lynch,
J.
Boyd
(1996)
Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1.
The New England journal of medicine, 335 19
-
D.
Bell,
A.
Berchuck,
M.
Birrer,
J.
Chien,
D.
Cramer,
F.
Dao,
R.
Dhir,
P.
Disaia,
H.
Gabra,
Pat
Glenn,
A.
Godwin,
J.
Gross,
L.
Hartmann,
M.
Huang,
D.
Huntsman,
M.
Iacocca,
M.
Imieliński,
S.
Kalloger,
B.
Karlan,
D.
Levine,
G.
Mills,
C.
Morrison,
D.
Mutch,
Narciso
Olvera,
S.
Orsulic,
K.
Park,
N.
Petrelli,
B.
Rabeno,
J.
Rader,
B.
Sikic,
K.
Smith-McCune,
A.
Sood,
D.
Bowtell,
R.
Penny,
J.
Testa,
K.
Chang,
H.
Dinh,
J.
Drummond,
G.
Fowler,
P.
Gunaratne,
A.
Hawes,
C.
Kovar,
L.
Lewis,
M.
Morgan,
I.
Newsham,
J.
Santibanez,
J.
Reid,
L.
Treviño,
Y.
Wu,
M.
Wang,
D.
Muzny,
D.
Wheeler,
R.
Gibbs,
G.
Getz,
M.
Lawrence,
K.
Cibulskis,
A.
Sivachenko,
C.
Sougnez,
Douglas
Voet,
Jane
Wilkinson,
Toby
Bloom,
K.
Ardlie,
T.
Fennell,
J.
Baldwin,
S.
Gabriel,
E.
Lander,
L.
Ding,
R.
Fulton,
D.
Koboldt,
M.
McLellan,
T.
Wylie,
Jason
Walker,
M.
O'Laughlin,
D.
Dooling,
L.
Fulton,
R.
Abbott,
N.
Dees,
Q.
Zhang,
C.
Kandoth,
M.
Wendl,
W.
Schierding,
D.
Shen,
C.
Harris,
H.
Schmidt,
Joelle
Kalicki,
K.
Delehaunty,
C.
Fronick,
Ryan
Demeter,
L.
Cook,
J.
Wallis,
L.
Lin,
V.
Magrini,
J.
Hodges,
James
Eldred,
S.
Smith,
C.
Pohl,
Fabio
Vandin,
Benjamin
Raphael,
G.
Weinstock,
E.
Mardis,
R.
Wilson,
M.
Meyerson,
W.
Winckler,
R.
Verhaak,
Suzie
Carter,
C.
Mermel,
G.
Saksena,
H.
Nguyen,
R.
Onofrio,
D.
Hubbard,
S.
Gupta,
A.
Crenshaw,
A.
Ramos,
L.
Chin,
A.
Protopopov,
Juinhua
Zhang,
T.
Kim,
I.
Perna,
Y.
Xiao,
Hailei
Zhang,
G.
Ren,
N.
Sathiamoorthy,
R.
Park,
E.
Lee,
P.
Park,
R.
Kucherlapati,
D.
Absher,
L.
Waite,
G.
Sherlock,
J.
Brooks,
Jun
Li,
Jin
Xu,
R.
Myers,
P.
Laird,
L.
Cope,
J.
Herman,
Hui
Shen,
D.
Weisenberger,
H.
Noushmehr,
F.
Pan,
T.
Triche,
B.
Berman,
D.
Berg,
J.
Buckley,
S.
Baylin,
P.
Spellman,
E.
Purdom,
P.
Neuvial,
H.
Bengtsson,
L.
Jakkula,
S.
Durinck,
J.
Han,
S.
Dorton,
H.
Marr,
Y.
Choi,
V.
Wang,
Ninghai
Wang,
J.
Ngai,
J.
Conboy,
B.
Parvin,
H.
Feiler,
T.
Speed,
J.
Gray,
N.
Socci,
Yanke
Liang,
B.
Taylor,
N.
Schultz,
L.
Borsu,
A.
Lash,
C.
Brennan,
A.
Viale,
C.
Sander,
M.
Ladanyi,
K.
Hoadley,
S.
Meng,
Y.
Du,
Yufeng
Shi,
Lulin
Li,
Y.
Turman,
D.
Zang,
E.
Helms,
S.
Balu,
X.
Zhou,
Jinhua
Wu,
M.
Topal,
D.
Hayes,
C.
Perou,
Jun
Zhang,
Chaowei
Wu,
S.
Shukla,
A.
Sivachenko,
R.
Jing,
Yueh-Feng
Liu,
M.
Noble,
H.
Carter,
D.
Kim,
R.
Karchin,
J.
Korkola,
Laura
Heiser,
R.
Cho,
Zhihao
Hu,
E.
Cerami,
A.
Olshen,
B.
Reva,
Yevgeniy
Antipin,
R.
Shen,
P.
Mankoo,
R.
Sheridan,
G.
Ciriello,
William
Chang,
J.
Bernanke,
D.
Haussler,
C.
Benz,
Joshua
Stuart,
S.
Benz,
J.
Sanborn,
Charles
Vaske,
Jiangyu
Zhu,
C.
Szeto,
G.
Scott,
C.
Yau,
M.
Wilkerson,
N.
Zhang,
R.
Akbani,
K.
Baggerly,
W.
Yung,
J.
Weinstein,
T.
Shelton,
D.
Grimm,
M.
Hatfield,
S.
Morris,
P.
Yena,
P.
Rhodes,
M.
Sherman,
J.
Paulauskis,
S.
Millis,
A.
Kahn,
J.
Greene,
R.
Sfeir,
M.
Jensen,
James
Chen,
J.
Whitmore,
S.
Alonso,
J.
Jordan,
A.
Chu,
Jinghui
Zhang,
A.
Barker,
C.
Compton,
G.
Eley,
M.
Ferguson,
P.
Fielding,
D.
Gerhard,
R.
Myles,
C.
Schaefer,
K.
Shaw,
J.
Vaught,
J.
Vockley,
P.
Good,
M.
Guyer,
B.
Ozenberger,
James
Peterson,
E.
Thomson
(2011)
Integrated Genomic Analyses of Ovarian Carcinoma
Nature, 474
-
H.
Farmer,
N.
Mccabe,
C.
Lord,
A.
Tutt,
Damian
Johnson,
T.
Richardson,
M.
Santarosa,
Krystyna
Dillon,
I.
Hickson,
C.
Knights,
N.
Martin,
S.
Jackson,
G.
Smith,
A.
Ashworth
(2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Nature, 434
-
J.
Ledermann,
P.
Harter,
C.
Gourley,
M.
Friedlander,
I.
Vergote,
G.
Rustin,
Clare
Scott,
W.
Meier,
R.
Shapira-Frommer,
T.
Safra,
D.
Matei,
A.
Fielding,
S.
Spencer,
B.
Dougherty,
M.
Orr,
D.
Hodgson,
J.
Barrett,
U.
Matulonis
(2014)
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
The Lancet. Oncology, 15 8
-
Joan
Walker,
C.
Powell,
Lee-may
Chen,
J.
Carter,
Victoria
Jump,
L.
Parker,
M.
Borowsky,
R.
Gibb
(2015)
Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer
Cancer, 121
-
B.
Kaufman,
R.
Shapira-Frommer,
R.
Schmutzler,
M.
Audeh,
M.
Friedlander,
J.
Balmaña,
G.
Mitchell,
G.
Fried,
S.
Stemmer,
A.
Hubert,
O.
Rosengarten,
M.
Steiner,
N.
Loman,
K.
Bowen,
A.
Fielding,
S.
Domchek
(2015)
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 3
-
P.
Dempsey
(2005)
2–13 Surveillance of BRCA1 and BRCA2 Mutation Carriers With Magnetic Resonance Imaging, Ultrasound, Mammography, and Clinical Breast Examination
-
BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study
-
M.
Audeh,
J.
Carmichael,
R.
Penson,
M.
Friedlander,
B.
Powell,
K.
Bell-McGuinn,
C.
Scott,
J.
Weitzel,
A.
Oaknin,
N.
Loman,
K.
Lu,
R.
Schmutzler,
U.
Matulonis,
M.
Wickens,
A.
Tutt
(2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
The Lancet, 376
-
A.
Hartlerode,
R.
Scully
(2009)
Mechanisms of double-strand break repair in somatic mammalian cells.
The Biochemical journal, 423 2
-
J.
Ledermann,
P.
Harter,
C.
Gourley,
M.
Friedlander,
I.
Vergote,
G.
Rustin,
C.
Scott,
W.
Meier,
R.
Shapira-Frommer,
T.
Safra,
D.
Matei,
E.
Macpherson,
C.
Watkins,
J.
Carmichael,
U.
Matulonis
(2012)
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.
The New England journal of medicine, 366 15
-
N.
Kauff,
J.
Satagopan,
M.
Robson,
Lauren
Scheuer,
M.
Hensley,
C.
Hudis,
N.
Ellis,
J.
Boyd,
P.
Borgen,
R.
Barakat,
L.
Norton,
M.
Castiel,
K.
Nafa,
K.
Offit
(2002)
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
The New England journal of medicine, 346 21
-
H.
Risch,
J.
McLaughlin,
D.
Cole,
B.
Rosen,
L.
Bradley,
E.
Kwan,
E.
Jack,
D.
Vesprini,
G.
Kuperstein,
J.
Abrahamson,
I.
Fan,
B.
Wong,
S.
Narod
(2001)
Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.
American journal of human genetics, 68 3
-
(2006)
Intraperitoneal cisplatin and paclitaxel in ovarian cancer
, 354
-
J.
Kotsopoulos,
B.
Rosen,
I.
Fan,
J.
Moody,
J.
McLaughlin,
H.
Risch,
T.
May,
P.
Sun,
S.
Narod
(2016)
Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status.
Gynecologic oncology, 140 1
-
(2009)
DNA repair in mammalian cells: DNA doublestrand break repair – how to fix a broken relationship
-
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation: an NRG Oncology/Gynecologic Oncology Group study
-
Da
Yang,
Sofia
Khan,
Yan
Sun,
K.
Hess,
I.
Shmulevich,
A.
Sood,
Wei
Zhang
(2011)
Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.
JAMA, 306 14
-
J.
Hamada,
D.
Nakata,
D.
Nakae,
Y.
Kobayashi,
H.
Akai,
Y.
Konishi,
F.
Okada,
T.
Shibata,
M.
Hosokawa,
T.
Moriuchi
(2001)
Increased oxidative DNA damage in mammary tumor cells by continuous epidermal growth factor stimulation.
Journal of the National Cancer Institute, 93 3
-
R.
Wooster,
S.
Neuhausen,
J.
Mangion,
Y.
Quirk,
D.
Ford,
N.
Collins,
K.
Nguyen,
S.
Seal,
T.
Tran,
D.
Averill
(1994)
Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13.
Science, 265 5181
-
Pablo
Huertas
(2010)
DNA resection in eukaryotes: deciding how to fix the break
Nature Structural &Molecular Biology, 17
-
C.
Griffiths
(1975)
Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma.
National Cancer Institute monograph, 42
